Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$1.12 CAD
Change Today 0.00 / 0.00%
Volume 105.8K
As of 3:59 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

stellar biotechnologies inc (KLH) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/14 - C$2.55
52 Week Low
07/21/14 - C$0.65
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

stellar biotechnologies inc (KLH) Related Businessweek News

No Related Businessweek News Found

stellar biotechnologies inc (KLH) Details

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

23 Employees
Last Reported Date: 11/21/14

stellar biotechnologies inc (KLH) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: $175.0K
Chief Operating Officer
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.

stellar biotechnologies inc (KLH) Key Developments

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Stellar Biotechnologies, Inc. for KLH-Conjugate Immunotherapy Signals Key Step for Novel Carrier Molecule

Stellar Biotechnologies, Inc. is encouraged that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for a KLH-based immunotherapy compound in the treatment of adult patients with EGFRvIII-positive glioblastoma being developed by Celldex Therapeutics, Inc. This important designation by the FDA is a first for a KLH-based immunotherapy. Stellar KLH(TM) is not being used by Celldex, however, there are a number of KLH-conjugate immunotherapies that are currently in clinical trial development in the U.S., Europe, or Asia for a variety of disease indications including cancers, autoimmune disorders, Alzheimer's, and inflammatory diseases, which are using Stellar KLH.

Stellar Biotechnologies, Inc. Announces Consolidated Earnings Results for the First Quarter Ended December 31, 2014

Stellar Biotechnologies, Inc. announced consolidated earnings results for the first quarter ended December 31, 2014. For the quarter, the company's total revenues were $212,661 compared with $58,825 a year ago. Net loss was $1,343,477 or $0.02 per basic and diluted share compared with $5,577,190 or $0.08 per basic and diluted share a year ago. The decreased loss in the first quarter was primarily affected by non cash changes in fair value of warrant liability. Net cash used in operating activities was $1,285,544 compared with $1,086,888 a year ago.

Stellar Biotechnologies, Inc. to Report Q1, 2015 Results on Feb 09, 2015

Stellar Biotechnologies, Inc. announced that they will report Q1, 2015 results on Feb 09, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KLH:CN C$1.12 CAD 0.00

KLH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KLH.
View Industry Companies

Industry Analysis


Industry Average

Valuation KLH Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.6x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STELLAR BIOTECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at